Actively Recruiting
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-08-12
48
Participants Needed
1
Research Sites
33 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.
CONDITIONS
Official Title
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign the informed consent form and be willing and able to follow the study protocol
- For healthy subjects: BMI between 18 and 28 kg/m2
- For patients: ECOG performance status 0-1
- For patients: Pathologically confirmed tumor
- For patients: Planned surgical resection or exploration, including primary or recurrent metastatic tumor
- For patients: Sufficient organ function
You will not qualify if you...
- Known severe allergic reactions or hypersensitivity to the test drug or its components, including alcohol allergy
- Received radionuclide diagnostic or therapeutic drugs less than 10 physical half-lives before administration
- Used intravenous iodinated contrast agent within 24 hours before administration
- Used high-density oral contrast agent within 5 days before administration (oral water-based contrast agents are allowed)
- Presence of concurrent infectious diseases
- Severe urinary incontinence, hydronephrosis, or severe urination dysfunction
- Severe active infection requiring intravenous antibiotics within 14 days before administration
- Unexplained fever above 38.5°C lasting more than 1 hour during screening or before administration
- Severe or poorly controlled cardiac diseases or symptoms, including NYHA class 2 or higher heart failure, unstable angina, myocardial infarction within 6 months, or prolonged QTcF interval (above 450 msec in males or 470 msec in females)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
Research Team
X
Xiao Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here